Generate Biomedicines Inc’s Lock-Up Period Will Expire on August 26th (NASDAQ:GENB)

Posted by Geri Gentry on Aug 23rd, 2026

Generate Biomedicines’ (NASDAQ:GENB – Get Free Report) lock-up period will end on Wednesday, August 26th. Generate Biomedicines had issued 25,000,000 shares in its public offering on February 27th. The total size of the offering was $400,000,000 based on an initial share price of $16.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. HC Wainwright lifted their price target on shares of Generate Biomedicines from $16.00 to $25.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Morgan Stanley upped their price objective on shares of Generate Biomedicines from $20.00 to $22.00 and gave the company an “overweight” rating in a research report on Thursday, May 14th. Weiss Ratings initiated coverage on Generate Biomedicines in a research note on Tuesday, August 11th. They set a “sell (d)” rating for the company. Finally, Wall Street Zen lowered Generate Biomedicines from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $25.40.

Check Out Our Latest Report on GENB

Generate Biomedicines Stock Performance

Generate Biomedicines stock opened at $16.12 on Friday. Generate Biomedicines has a 52 week low of $11.00 and a 52 week high of $18.18. The stock has a market cap of $2.07 billion and a PE ratio of -10.14. The firm’s 50 day simple moving average is $14.96.

Generate Biomedicines (NASDAQ:GENB – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). The company had revenue of $6.31 million for the quarter. Equities analysts forecast that Generate Biomedicines will post -2.29 EPS for the current year.

Institutional Investors Weigh In On Generate Biomedicines

Hedge funds and other institutional investors have recently modified their holdings of the stock. Susquehanna International Group LLP bought a new position in shares of Generate Biomedicines during the second quarter worth about $196,000. Bank of New York Mellon Corp acquired a new position in Generate Biomedicines in the second quarter worth about $967,000. AXQ Capital LP bought a new stake in Generate Biomedicines in the second quarter valued at about $218,000. Finally, Braidwell LP bought a new stake in Generate Biomedicines in the second quarter valued at about $55,398,000.

Generate Biomedicines Company Profile

(Get Free Report)

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.